Gender Dysphoria Treatment

Coverage Summary

This policy, CS145.R (Gender Dysphoria Treatment), is effective August 1, 2025 and addresses coverage criteria for gender-affirming surgical and ancillary services (breast/chest procedures, genital GAS, voice/thyroid cartilage procedures, and related services). The policy's overall coverage stance is mixed — coverage is available for multiple gender-affirming procedures when specified documentation, age limits, and prerequisites are met, but some ancillary/cosmetic procedures may be excluded and evidence quality varies. This Medical Policy does not apply to the state of Maryland; providers should refer to the Maryland Department of Health Gender-Affirming Treatment Services under the Maryland Medicaid Program for state-specific coverage.

Surface thresholds

Age for breast augmentation>= 18 years

Age for mastectomy or breast reduction>= 18 years (individuals within one calendar year of turning 18 can be considered on a case-by-case basis)

Voice masculinization hormone therapy duration6 months continuous prior to surgery

Breast augmentation hormone therapy duration12 months continuous prior to the breast procedure

Genital surgery real-life experience duration12 months continuous full-time real-life involvement in the identified gender

Genital surgery hormone therapy duration12 months continuous hormone therapy appropriate for the experienced gender (unless medically contraindicated or not indicated)

Medical-Necessity Criteria

Breast surgery (mastectomy, breast reduction, breast augmentation) coverage criteria

Covered when ALL of the following are met:

ALL of the following

Written clinical assessment from at least one Qualified Healthcare Professional experienced in treating Gender Dysphoria documenting persistent, well-documented Gender Dysphoria.
Capacity to make a fully informed decision and to consent for treatment.
Favorable psychosocial-behavioral evaluation to screen for risk factors or potential postoperative challenges.
Age requirements: must be at least 18 years of age for breast augmentation; must be at least 18 years of age for mastectomy or breast reduction, with individuals within one calendar year of turning 18 considered on a case-by-case basis.

Evidence Summary and Coverage Implications

Summarized evidence and coverage implications: Genital GAS - coverage is permitted when the policy's documentation and multidisciplinary criteria are met; the evidence base is low to very low quality with heterogeneous outcomes across techniques (metoidioplasty vs radial forearm flap phalloplasty) and high complication/urethral complication rates reported. Vaginoplasty - evidence is heterogeneous and mostly retrospective (penile skin inversion and bowel techniques), with neovaginal/introital stenosis and variable outcome measures reported. Hair removal - limited data suggest laser/electrolysis can be moderately effective as preoperative preparation for genital reconstruction but permanence is not guaranteed and evidence is sparse. Facial feminization - limited, low-quality studies suggest potential improvements in satisfaction and quality of life but long-term and standardized outcome data are lacking. Body contouring - evidence is very limited (small, poor-quality studies); procedures may improve appearance and quality of life for some patients but safety/efficacy data are insufficient. Adolescents - evidence for GAS in adolescents is scarce; chest masculinization may show psychological benefit but genital surgery evidence is minimal or unclear and timing is individualized. Professional society guidance (Endocrine Society, AAP, ACOG) generally recommends multidisciplinary assessment, delaying major genital surgeries until the age of majority (typically ≥ 18 years), and usually requiring about 12 months of hormone therapy prior to genital surgery (with specified exceptions) and other procedure-specific hormone-duration prerequisites (e.g., 6 months for voice masculinization).

Evidence / Source	Key finding / limitations
USTS secondary analysis (Almazan et al., 2021)
Association between prior gender-affirming surgery and lower odds of psychological distress, tobacco use, and suicidal ideation; limitations: self-report, nonprobability sampling, potential confounding
Systematic reviews (Wernick 2019; Oles et al. 2022; Hayes reports)
Most studies suggest psychological benefits (quality of life, body image) after GAS but overall evidence limited by heterogeneous measures, retrospective designs, and low-moderate quality
Phalloplasty outcomes systematic review (Wang et al., 2022)
High overall complication rates (e.g., urethral fistula/stricture); functional outcomes variably reported; evidence weak and lacking standardized outcomes
Metoidioplasty vs RFFP systematic review (Frey et al., 2016)
Metoidioplasty may have higher single-stage completion, better aesthetic and erogenous sensation, and lower complication rates vs RFFP; evidence low to very low quality
Vaginoplasty reviews (Horbach et al., 2015; Bouman et al., 2014; Bustos et al., 2021)
Techniques heterogeneous; neovaginal/introital stenosis common; satisfaction often high but outcome measures inconsistent and studies mostly retrospective/low quality
Hair removal evidence (Zhang 2016; Hayes evolving review)
Limited data; LHR moderately effective and satisfactory when appropriately selected; not guaranteed permanent; better results if no prior mechanical epilation
Facial feminization and body-contouring (Hayes, Coon et al., Siringo et al.)
Limited, mostly poor-quality studies suggesting potential improvements in satisfaction and quality of life; lack of standardized patient-reported measures and long-term data
Adolescents evidence (Hayes reviews; Thompson; Mahfouda)
Evidence scarce for adolescents; chest surgery may have psychological benefits but genital GAS safety/efficacy and long-term outcomes unclear; recommendations emphasize case-by-case multidisciplinary assessment
Policy procedural and coverage rationale (UnitedHealthcare CS145.R)
Lists covered procedures, documentation requirements, age and hormone therapy thresholds, and notes policy exclusion for certain states (e.g., Maryland); emphasizes federal/state/contractual determinations

Coding (reference)

Listed CPT procedures (reference list; inclusion does not guarantee coverage)CPT

11950	Subcutaneous injection of filling material; 1 cc or less
11951	Subcutaneous injection of filling material; 1.1 to 5.0 cc
11952	Subcutaneous injection of filling material; 5.1 to 10.0 cc
11954	Subcutaneous injection of filling material; over 10.0 cc
14000	Adjacent tissue transfer or rearrangement, trunk; defect 10 sq cm or less
14001	Adjacent tissue transfer or rearrangement, trunk; defect 10.1 to 30.0 sq cm
14041	Adjacent tissue transfer; forehead/cheek/chin/mouth/neck/axillae/genitalia/hands/feet; defect 10.1 to 30.0 sq cm
15734	Muscle, myocutaneous, or fasciocutaneous flap; trunk
15738	Muscle, myocutaneous, or fasciocutaneous flap; lower extremity
15750	Flap; neurovascular pedicle

1–10 of 135

1/14

Listed ICD-10 diagnosis codesICD-10

F64.0	Transsexualism
F64.1	Dual role transvestism
F64.2	Gender identity disorder of childhood
F64.8	Other gender identity disorders
F64.9	Gender identity disorder, unspecified
Z87.890	Personal history of sex reassignment

Listing of CPT and ICD-10 codes in this policy is provided for reference only; inclusion of a code does not imply the service is covered or reimbursable. Coverage and reimbursement are determined by federal, state, or contractual requirements and applicable laws, and the codes in the policy do not guarantee payment.

Provider Actions & Documentation Requirements

Documentation Required

Qualified Healthcare Professional assessment(s)

A written clinical assessment from a Qualified Healthcare Professional (QHP) experienced in treating Gender Dysphoria is required. The assessment must document the diagnosis, capacity to consent, and that the individual meets applicable age and psychosocial criteria.

Persistent, well-documented Gender Dysphoria
Capacity to make a fully informed decision and to consent for treatment
Documented age requirement where applicable (see policy age-specific criteria)

Documentation Required

Psychosocial-behavioral evaluation

A psychosocial-behavioral evaluation is required to screen for and identify risk factors or potential postoperative challenges. The evaluation should be performed by a behavioral health professional experienced in gender-affirming care and include treatment recommendations and any identified supports or risk mitigation strategies.

Definitions

Qualified Healthcare ProfessionalDocumented credentials from a relevant licensing board; minimum of a master's degree or equivalent training in a clinical field relevant to assessment/treatment of Gender Dysphoria; knowledge and experience in treating Gender Dysphoria.

Gender Dysphoria (adolescents and adults)Marked incongruence between experienced/expressed gender and assigned gender for at least 6 months with DSM-5-TR criteria and associated clinically significant distress or impairment.

Gender Dysphoria (children)Marked incongruence for at least 6 months with at least six specified criteria (one must be criterion A1) and associated clinically significant distress or impairment.

GASGender-affirming surgery (gender-affirming surgical procedures for treatment of Gender Dysphoria).

MHPMental Health Practitioner (provider involved in assessment/recommendation for gender-affirming interventions).

RFFP

Revision History

2025-08-01effective_dateLatest

Policy effective date set to August 1, 2025 (CS145.R).

2025-08-01material_change

Added language that this Medical Policy does not apply to the state of Maryland; providers should refer to the Maryland Department of Health Gender-Affirming Treatment Services under the Maryland Medicaid Program.

2025-08-01archived_previous_version

Archived previous policy version CS145.Q.